CT Myocardial Perfusion to Guide the Diagnosis and Treatment of Patients With Stable Coronary Artery Disease (POTENTIAL)
NCT ID: NCT06119022
Last Updated: 2023-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
660 participants
INTERVENTIONAL
2023-09-30
2025-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quantitative Analysis of Functional CT Imaging of Coronary Atherosclerosis
NCT04986410
PET MYOCARDIAL Blood Flow Comparison to Coronary CTA and CT-FFR
NCT05349084
Viable Myocardium Detected by Hybrid PET/MR and SPECT for the Prediction of the Efficacy of PCI in Patients With CTO.
NCT06113835
CCTA Improves Clinical Management of Stable Chest Pain
NCT04691037
SPECT Fibroblast Activation Protein Imaging in Patients With Cardiac Disease
NCT06326970
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
CT-MPI guided without myocardial ischemia
There was no evidence of myocardial ischemia in patients with coronary heart disease by CT-MPI
routine medical treatment
Patients with negative myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to have routine medical therapy instead of invasive coronary angiography.
CT-MPI guided with myocardial ischemia
There was positive evidence of myocardial ischemia in patients with coronary heart disease by CT-MPI
Invasive coronary angiography
Patients with positive myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to undergo invasive coronary angiography.
SPECT-MPI guided without myocardial ischemia
There was no evidence of myocardial ischemia in patients with coronary heart disease by SPECT-MPI
routine medical treatment
Patients with negative myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to have routine medical therapy instead of invasive coronary angiography.
SPECT-MPI guided with myocardial ischemia
There was positive evidence of myocardial ischemia in patients with coronary heart disease by SPECT-MPI
Invasive coronary angiography
Patients with positive myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to undergo invasive coronary angiography.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Invasive coronary angiography
Patients with positive myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to undergo invasive coronary angiography.
routine medical treatment
Patients with negative myocardial ischemia either in CT-MPI guided arm or SPECT-MPI guided arm will scheduled to have routine medical therapy instead of invasive coronary angiography.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with stable chest pain who have undergone coronary CT angiography and have 50-90% stenosis in at least one vessel \> 2mm in diameter
* Able to provide signed informed consent
Exclusion Criteria
* Evidence of clinical instability or need for an emergent procedure
* History of percutaneous coronary stent implantation, history of coronary artery bypass grafting, or history of myocardial infarction
* Left main artery stenosis ≥ 50%
* Severe heart failure (New York Heart Association (NYHA) ≥III)
* Estimated glomerular filtration rate \< 60 mL/min/1.73 m2
* Contraindicated to use contrast agents, beta-blockers, nitrates or adenosine drugs
* Acute episodes of bronchial asthma or chronic obstructive pulmonary disease
* II or III degree atrioventricular block
* History of pacemaker or implantable cardioverter defibrillator implantation
* Combined with other cardiovascular diseases including cardiomyopathy, congenital heart disease, valvular heart disease, pulmonary vascular disease, pericardial disease, etc
* Pregnant or trying to be pregnant
* Combined with any other serious disease, life expectancy \<1 year
* Any condition leading to possible inability to comply with the protocol procedures and follow-up
* Currently participating in any other clinical trials
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chinese Academy of Medical Sciences, Fuwai Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Bin Lu
Director of Radiologic Imaging
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fu Wai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Fuwai Central China Cardiovascular Hospital
Zhengzhou, Henan, China
The First Affiliated Hosptial of Zhengzhou University
Zhengzhou, Henan, China
The Second Norman Bethune Hospital of Jilin University
Changchun, Jilin, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-GSP-GG-21
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.